chemotherapy resistance
Identification of driver genes associated with chemotherapy resistance of Ewing’s sarcoma
... LIMMA package R to analyze and obtain DEGs between tissues from patients who experienced a relapse (REL) and from those with no evidence of disease (NED). Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes ...
10
NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma
... Results: NAP1L1 expression was significantly upregulated in tumor tissues as compared to adjacent non‑tumor tissues. High NAP1L1 expression in HCC tissues was associated with aggressive clinicopathologic features, such ...
11
Non-Coding RNAs Mediate Chemotherapy Resistance in Ovarian Cancer
... with chemotherapy resistance in ovarian ...paclitaxel resistance in ovarian cancer cells and human tumour ...with chemotherapy resistance, including cisplatin and pactitaxel (Table ...
16
CMTM1 v17 is associated with chemotherapy resistance and poor prognosis in non small cell lung cancer
... analyzing chemotherapy efficacy in the correlation of the expression level of CMTM1_v17, patients with low CMTM1_v17 expression in the tumor tissues after NAC suggested higher PR rates than those with high ...
10
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
... Recent research has suggested potential novel therapeutic targets for drug-resistant MBC. Tumor stem cells have been identifi ed in many malignancies, includ- ing breast cancer [19,20]. Accumulation of drug resis- tance ...
12
Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia
... Hypoxia leads to reactive oxygen species (ROS) imbalance, which is proposed to associate with drug resistance and oncogenesis. Inhibition of enzymes of antioxidant balancing system in tumor cells was shown to ...
14
Specific microRNAs as novel biomarkers for combination chemotherapy resistance detection of colon adenocarcinoma
... The patients were recruited in this study. Patients were excluded from the study if they had a clinical diagnosis of hereditary nonpolyposis colon cancer, or if they had undergone chemotherapy or radiotherapy for ...
9
A theoretical quantitative model for evolution of cancer chemotherapy resistance
... evolve resistance to these drugs ultimately resulting in treatment failure and cancer ...for chemotherapy failure in cancer treatment reside in multiple levels: poor vascularization, hypoxia, intratumoral ...
17
Kallikrein-related peptidase 6 induces chemotherapeutic resistance by attenuating auranofin-induced cell death through activation of autophagy in gastric cancer
... KLK6 expression is increased in many types of tumors and this elevation is related with more aggressive symptoms and poor prognosis [28, 40, 41]; however, the role of KLK6 in the relationship between autophagy regulation ...
17
Original Article Expression of NF-κB and PTEN in primary epithelial ovarian carcinoma and the correlation with chemoresistance
... with chemotherapy resistance in ovarian cancer by measuring their expression in primary epithelial ovarian cancer, and to explore the correlation of the expression of these two proteins with ovarian ...
11
The role of Hippo signal pathway in breast cancer metastasis
... Abstract: The Hippo pathway is a novel and highly conserved mammalian signaling pathway. Mutations and altered expression of core Hippo pathway components promote the migration, invasion, malignancy, and ...
9
Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy
... to chemotherapy leads to altered cell cycle gene ...with chemotherapy resistance, whereas increased or no change in the expression of proliferation genes after chemotherapy predicts ...
13
In-hospital individualized prescriptive exercise intervention for acute leukemia patients undergoing chemotherapy
... According to hypothesis three, it was assumed that there would be no significant differences pre-to-post on cardiovascular endurance time on the recumbent cycle ergometer. In this study, due to the small sample size the ...
75
Genetic and molecular alterations in olfactory neuroblastoma: implications for pathogenesis, prognosis and treatment
... neoangiogenesis. Bcl-2 acts as an anti-apoptotic factor but also contributes to the HIF-1a/Epo/EpoR/Bcl-2 system involved in angiogenesis [23]. hASH1 activates BCL-2 transcription, so Bcl-2 inhibitors are promising ...
13
Risk factors associated with community-acquired CTX-M producing Klebsiellapneumoniae typing by Rep-PCR in Sanandaj, Iran
... Urinary catheters, especially when used for a long time, are among the most important factors that help develop urinary tract infection and sometimes bacteremia. In this study, urinary catheter has not been identified as ...
7
Tubeimoside-I sensitizes colorectal cancer cells to chemotherapy by inducing ROS-mediated impaired autophagolysosomes accumulation
... Adjuvant chemotherapy is the main treatment strategy for advanced CRC, however, a subset of patients eventually become re- lapsed because of acquired drug resistance to the current commonly used ...
13
High expression of <em>S100A8</em> gene is associated with drug resistance to etoposide and poor prognosis in acute myeloid leukemia through influencing the apoptosis pathway
... In summary, our retrospective study demonstrated the transcription level of S100A8 in AML were significantly associated with disease prognosis and could potentially be used as a marker of future novel therapeutic ...
13
Cancer Chemosensitivity Testing: Review
... TAXEL-based chemotherapy is selected, testing on DNA repair and the mutation of tubuline to assess the resistence to cDDP and TAXEL, then decide to use either cDDP-based or Texane-based ...
8
Noncoding RNAs in cancer therapy resistance and targeted drug development
... MiR-181a is another example that mediates chemo- sensitivity. In patients with acute myeloid leukemia (AML) treated with similar intensive induction therapy regimens, a higher expression level of miR-181a was strongly ...
15
Efficacy of pemetrexed-based regimens in advanced non–small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review
... to the development of new targeted therapeutic approaches. EGFR-tyrosine kinase inhibitors (TKIs) are now the pre- ferred first-line therapy for patients with advanced non- squamous NSCLC with activating EGFR mutations, ...
9